Platelet-derived growth factor receptor beta serum concentrations during first-line therapy in ovarian cancer

Oncology (Switzerland)

Volumn 85, Issue 2, 2013, Pages 69-77

  Mathey, Sabrina ^a   Graeser, Monika Karla ^a   Zu Eulenburg, Christine ^a   Woelber, Linn ^a   Trillsch, Fabian ^a   Jaenicke, Fritz ^a   Müller, Volkmar ^a   Milde Langosch, Karin ^a   Mahner, Sven ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Angiogenesis; Biomarker; Ovarian cancer; Platelet derived growth factor receptor beta

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; VASCULOTROPIN 165; ANGIOGENESIS INHIBITOR; BIOLOGICAL MARKER; PLATINUM DERIVATIVE; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; ANGIOGENESIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURGERY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-125 ANTIGEN; CARBOPLATIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84880183962     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000351032     Document Type: Article

References (37)

1. American Cancer Society: Cancer Facts and Figures. Atlanta, American Cancer Society, 2012.
2. Du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, et al: A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first line-treatment of ovarian cancer. J Natl Cancer Inst 2003; 95: 1320-1329.
3. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, et al: Incoporation of bevacizumb in the primary treatment of ovarian cancer. N Engl J Med 2011; 365: 2473-2483.
4. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al: A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365: 2484-2496.
5. Bast RC Jr, Badgwell D, Lu Z, Marquez R, et al: New tumor markers: CA125 and beyond. Int J Gynecol Cancer 2005; 15(suppl 3):274- 281.
6. Rustin GJ, Bast RC Jr, Kelloff GJ, Barrett JC, Carter SK, et al: Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin Cancer Res 2004; 10: 3919-3926.
7. Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, et al: Potential markers that complement expression of CA125 in epithelian ovarian cancer. Gynecol Oncol 2005; 99: 267-277.
8. Rubin SC, Hoskins WJ, Hakes TB, Markman M, Reichman BS, et al: Serum CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer. Am J Obstet Gynecol 1989; 160: 667- 671.
9. Oikawa T, Onozawa C, Sakaguchi M, Morita I, Murota S: Three isoforms of platelet derived growth factors all have the capability to induce angiogenesis in vivo. Biol Pharm Bull 1994; 17: 1686-1688.
10. Risau W, Drexler H, Mironov V, et al: Platelet derived growth factor is angiogenic in vivo. Growth Factors 1992; 7: 261-266.
11. Dong J, Grunstein J, Tejada M, Peale F, et al: VEGF-null cells require PDGFR alpha signaling- mediated stromal fibroblast recruitment for tumorigenesis. EMBO J 2004; 23: 2800- 2810.
12. Lafuente JV, Adan B, Alkiza K, Garibi JM, et al: Expression of vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor-beta (PDGFR-beta) in human gliomas. J Mol Neurosci 1999; 13: 177-185.
13. Lu C, Thaker PH, Linn YG, et al: Impact of vessel maturation on antigiogenic therapy in ovarian cancer. Am J Obstet Gynecol 2008; 198: 477-479.
14. Matei D, Kelich S, Cao L, Menning N, et al: PDGF BB induces VEGF secretion in ovarian cancer. Cancer Biol Ther 2007; 6: 1951-1959.
15. Ledermann JA, Hackshaw A, Kaye S, Jayson G, et al: Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol 2011; 29: 3798-3804.
16. Eriksson A, Siegbahn A, Westermark B, Heldin CH, et al: PDGF alpha- and beta-receptors activate unique and common signal transduction pathways. EMBO J 1992; 11: 543-550.
17. Hart CE, Forstrom JW, Kelly JD, Seifert RA, et al: Two classes of PDGF receptor recognize different isoforms of PDGF. Science 1988; 240: 1529-1531.
18. Matsui T, Heidaran M, Miki T, Popescu N, et al: Isolation of a novel receptor cDNA establishes the existence of two PDGF receptor genes. Science 1989; 243: 800-804.
19. Henriksen R, Funa K, Wilander E, Backstrom T, et al: Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res 1993; 53: 4550-4554.
20. Matei D, Chang DD, Jeng MH: Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation. Clin Cancer Res 2004; 10: 681-690.
21. Schmandt RE, Broaddus R, Lu KH, Shvartsman H, et al: Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer 2003; 98: 758-764.
22. Yao R, Cooper GM: Requirement for phosphatidylinositol- 3 kinase in the prevention of apoptosis by nerve growth factor. Science 1995; 267: 2003-2006.
23. Greenhalgh DG, Sprugel KH, Murray MJ, Ross R: PDGF and FGF stimulate wound healing in the genetically diabetic mouse. Am J Pathol 1990; 136: 1235-1246.
24. Huang JS, Huang SS, Deuel TF: Transforming protein of Simian sarcoma virus stimulates autocrine growth of SSV-transformed cells through PDGF cell-surface receptors. Cell 1984; 39: 79-87.
25. Uren A, Yu JC, Gholami NS, Pierce JH, et al: The alpha PDGFR tyrosine kinase mediates locomotion of two different cell types through chemotaxis and chemokinesis. Biochem Biophys Res Commun 1994; 204: 628- 634.
26. Yu J, Moon A, Kim HR: Both platelet-derived growth factor receptor (PDGFR)-alpha and PDGFR-beta promote murine fibroblast cell migration. Biochem Biophys Res Commun 2001; 282: 697-700.
27. Woelber L, Mueller V, Eulenburg C, Schwarz J, Carney W, et al: Serum carbonic anhydrase IX during first-line therapy of ovarian cancer. Gynecol Oncol 2010; 117: 183-188.
28. Salven P, Manpaa H, Orpana A, Aitalo K, Joensuu H: Serum vascular endothelial growth factor is often elevated in disseminated cancer. Clin Cancer Res 1997; 3: 647-651.
29. Wong C, Wellman TL, Lounsbury KM: VEGF and HIF-1alpha expression are increased in advanced stages of epithelial ovarian cancer. Gynecol Oncol 2003; 91: 513-517.
30. Gadducci A, Ferdeghini M, Fanucchi A, Annicchiarico C, et al: Serum preoperative vascular endothelial growth factor (VEGF) in epithelial ovarian cancer: relationship with prognostic variables and clinical outcome. Anticancer Res 1999; 19: 1401-1405.
31. Li L, Wang L, Zhang W, Tang B, et al: Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer. Anticancer Res 2004; 24: 1973-1979.
32. Donnem T, Al-Saad S, al-Shibli K, Andersen S, Busund LT, et al: Prognostic impact of platelet-derived growth factors in non-small cell lung cancer tumor and stromal cells. J Thorac Oncol 2008; 3: 963-970.
33. Ostman A: PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev 2004; 15: 275-286.
34. Schilder RJ, Sill MW, Lee RB, Shaw TJ, Senterman MK, et al: Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2008; 26: 3418-3425.
35. Paulsson J, Sjoblom T, Micke P, Ponten F, Landberg G, et al: Prognostic significance of stromal platelet-derived growth factor betareceptor expression in human breast cancer. Am J Pathol 2009; 175: 334-341.
36. Stice LL, Vaziri C, Faller DV: Regulation of platelet-derived growth factor signaling by activated p21ras. Frontiers Biosci 1999; 4: 72-86.
37. Svendsen MN, Werther K, Nielsen HJ, Kristjansen PE: VEGF and tumor angiogenesis. Impact of surgery, wound healing, inflammation and blood transfusion. Scand J Gastroenterol 2002; 37: 373-379.